In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Arbor to acquire XenoPort for $467mm

Executive Summary

Private specialty pharmaco Arbor Pharmaceuticals LLC plans to acquire public drug delivery biotech XenoPort Inc. (mostly focused on neurological disorders) with a tender offer of $7.03 per share (a 65% premium), or about $467mm. The XenoPort board has unanimously agreed to the deal. In a concurrent financing, Arbor raised debt funding from Deutsche Bank to support the transaction.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Includes Contract
    • Payment Includes Cash

Related Companies